Johann S. de Bono The Institute of Cancer Research: and the Royal Marsden NHS Foundation Trust Biography Publications Institution JoVE Articles Johann S. de Bono has not added a biography. If you are Johann S. de Bono and would like to personalize this page please email our Author Liaison for assistance. Publications Targeting Myeloid Chemotaxis to Reverse Prostate Cancer Therapy Resistance Nature. Nov, 2023 | Pubmed ID: 37844613 Unbiased Differential Proteomic Profiling Between Cancer-associated Fibroblasts and Cancer Cell Lines Journal of Proteomics. Sep, 2023 | Pubmed ID: 37481068 Critical Role of Antioxidant Programs in Enzalutamide-resistant Prostate Cancer Oncogene. Jul, 2023 | Pubmed ID: 37355762 External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. May, 2023 | Pubmed ID: 37040594 A Transgender Patient with Prostate Cancer: Lessons Learnt European Urology. Apr, 2023 | Pubmed ID: 36609007 Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers Molecular Cancer Research : MCR. Jun, 2022 | Pubmed ID: 35302608 A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer Annual Review of Pharmacology and Toxicology. Jan, 2022 | Pubmed ID: 34449248 Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and Its Therapeutic Implications European Urology Focus. Sep, 2022 | Pubmed ID: 34167925 Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Repair Alterations (TALAPRO-1): an Open-label, Phase 2 Trial The Lancet. Oncology. 09, 2021 | Pubmed ID: 34388386 Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial Cancer Discovery. Nov, 2021 | Pubmed ID: 34045297 Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors European Urology. Feb, 2021 | Pubmed ID: 33176972 First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors Cancer Discovery. Jan, 2021 | Pubmed ID: 32988960 Intermittent Schedules of the Oral RAF-MEK Inhibitor CH5126766/VS-6766 in Patients with RAS/RAF-mutant Solid Tumours and Multiple Myeloma: a Single-centre, Open-label, Phase 1 Dose-escalation and Basket Dose-expansion Study The Lancet. Oncology. Nov, 2020 | Pubmed ID: 33128873 First-in-human Phase 1 Open Label Study of the BET Inhibitor ODM-207 in Patients with Selected Solid Tumours British Journal of Cancer. Dec, 2020 | Pubmed ID: 32989226 Prostate Cancer 2020: "The Times They Are A'Changing" Cancer Cell. Jul, 2020 | Pubmed ID: 32663466 Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel JNCI Cancer Spectrum. Apr, 2020 | Pubmed ID: 32368717 Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer with DNA Repair Gene Aberrations (TOPARP-B): a Multicentre, Open-label, Randomised, Phase 2 Trial The Lancet. Oncology. Jan, 2020 | Pubmed ID: 31806540 Androgen Receptor-modulatory MicroRNAs Provide Insight into Therapy Resistance and Therapeutic Targets in Advanced Prostate Cancer Oncogene. Jul, 2019 | Pubmed ID: 31043708 PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers European Urology. Oct, 2019 | Pubmed ID: 30954315 Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint European Urology. Jun, 2019 | Pubmed ID: 30528222 Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and Without PTEN Loss Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2019 | Pubmed ID: 30037818 Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles Cancers. Oct, 2018 | Pubmed ID: 30384500 Metastatic Prostate Cancer The New England Journal of Medicine. Feb, 2018 | Pubmed ID: 29412780 Development of Bag-1L As a Therapeutic Target in Androgen Receptor-dependent Prostate Cancer ELife. Aug, 2017 | Pubmed ID: 28826504 A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2017 | Pubmed ID: 28645941 Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids Clinical Genitourinary Cancer. Dec, 2017 | Pubmed ID: 28606735 A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Sep, 2017 | Pubmed ID: 28490463 Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care? European Urology. Aug, 2017 | Pubmed ID: 28233594 The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2017 | Pubmed ID: 27678453 Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Sep, 2016 | Pubmed ID: 27330057 Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, Et Al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31 European Urology. Dec, 2016 | Pubmed ID: 27240941 Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer European Urology. Oct, 2016 | Pubmed ID: 27117751 Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer European Urology. Nov, 2016 | Pubmed ID: 26965561 Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer Radiology. Jul, 2016 | Pubmed ID: 26807894 Sequencing of Agents in Castration-resistant Prostate Cancer The Lancet. Oncology. Jun, 2015 | Pubmed ID: 26065613 Baseline Neutrophil-lymphocyte Ratio (NLR) is Associated with Survival and Response to Treatment with Second-line Chemotherapy for Advanced Prostate Cancer Independent of Baseline Steroid Use Annals of Oncology : Official Journal of the European Society for Medical Oncology. Apr, 2015 | Pubmed ID: 25538172 External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone European Urology. Jul, 2014 | Pubmed ID: 24685433 First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2013 | Pubmed ID: 24065624 Continued Targeting of Androgen Receptor Signalling: a Rational and Efficacious Therapeutic Strategy in Metastatic Castration-resistant Prostate Cancer European Journal of Cancer (Oxford, England : 1990). Sep, 2011 | Pubmed ID: 21943974 Translating Scientific Advancement into Clinical Benefit for Castration-resistant Prostate Cancer Patients Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jun, 2011 | Pubmed ID: 21680542 Utilizing Circulating Tumor Cells: Challenges and Pitfalls Current Opinion in Genetics & Development. Feb, 2011 | Pubmed ID: 21112767 Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis Kaitriana E. Colling*1,2, Emily L. Symons*1, Lorenzo Buroni*3, Hiruni K. Sumanasiri1, Jessica Andrew-Udoh1, Emily Witt1,4, Haley A. Losh1, Abigail M. Morrison1, Kimberly K. Leslie5, Christopher J. Dunnill6, Johann S. de Bono3, Kristina W. Thiel1,7 1Department of Obstetrics and Gynecology, Carver College of Medicine, University of Iowa, 2Cancer Biology Graduate Program, Carver College of Medicine, University of Iowa, 3The Institute of Cancer Research: and the Royal Marsden NHS Foundation Trust, 4Department of Radiation Oncology, Carver College of Medicine, University of Iowa, 5Division of Molecular Medicine, Departments of Internal Medicine and Obstetrics and Gynecology, University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, 6Agilent Technologies, 7Holden Comprehensive Cancer Center, University of Iowa JoVE 66072 Pesquisa do câncer
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis Kaitriana E. Colling*1,2, Emily L. Symons*1, Lorenzo Buroni*3, Hiruni K. Sumanasiri1, Jessica Andrew-Udoh1, Emily Witt1,4, Haley A. Losh1, Abigail M. Morrison1, Kimberly K. Leslie5, Christopher J. Dunnill6, Johann S. de Bono3, Kristina W. Thiel1,7 1Department of Obstetrics and Gynecology, Carver College of Medicine, University of Iowa, 2Cancer Biology Graduate Program, Carver College of Medicine, University of Iowa, 3The Institute of Cancer Research: and the Royal Marsden NHS Foundation Trust, 4Department of Radiation Oncology, Carver College of Medicine, University of Iowa, 5Division of Molecular Medicine, Departments of Internal Medicine and Obstetrics and Gynecology, University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, 6Agilent Technologies, 7Holden Comprehensive Cancer Center, University of Iowa JoVE 66072 Pesquisa do câncer